A patient who started moxifloxacin on Wednesday now presents with a rash on the buttocks and pruritus of the oral mucosa; what is the appropriate management?

Immediate Management: Discontinue Moxifloxacin

Stop moxifloxacin immediately—this patient is experiencing a drug-induced cutaneous reaction with mucosal involvement that requires prompt discontinuation to prevent progression to severe cutaneous adverse reactions (SCARs). 1

Clinical Assessment

This presentation represents a non-severe delayed-type hypersensitivity reaction to moxifloxacin, manifesting as:

• Rash on buttocks (delayed maculopapular exanthem)
• Oral mucosal pruritus (possible early mucosal involvement)
• Onset after several days of therapy (started Wednesday, symptoms "yesterday")

The FDA labeling explicitly states to stop moxifloxacin at the first sign of skin rash and seek immediate medical attention, as skin rash may signal a more serious reaction 1. Moxifloxacin is specifically noted to have the highest risk of anaphylaxis among commonly used fluoroquinolones 2, 3.

Why This Matters

Mucosal involvement is a red flag. While isolated maculopapular rashes are the most common fluoroquinolone allergic reaction (2-3% incidence) 2, the addition of oral mucosal symptoms raises concern for potential progression to:

• Stevens-Johnson syndrome (SJS)
• Toxic epidermal necrolysis (TEN)
• Drug reaction with eosinophilia and systemic symptoms (DRESS)
• Acute generalized exanthematous pustulosis (AGEP)

These severe reactions are absolute contraindications to any future fluoroquinolone rechallenge 2.

Immediate Actions

1. Discontinue moxifloxacin immediately 1

2. Assess for SCAR features:

   • Fever
   • Facial edema or angioedema
   • Blistering or skin detachment
   • Extensive mucosal involvement (conjunctival, genital, oral)
   • Lymphadenopathy
   • Systemic symptoms (hepatitis, nephritis)

3. Symptomatic management:

   • Oral antihistamines (H1-blockers) for pruritus 2
   • Topical corticosteroids for localized rash
   • If progression occurs: systemic corticosteroids (0.5-1 mg/kg/day prednisone equivalent) 2

4. Document the reaction thoroughly:

   • Exact timeline (onset relative to drug initiation)
   • Distribution and morphology of rash
   • Presence of mucosal involvement
   • Any systemic symptoms
   • Label as "moxifloxacin allergy—delayed cutaneous reaction with mucosal involvement"

Alternative Antibiotic Selection

Do not use any fluoroquinolone. Cross-reactivity within the fluoroquinolone class for delayed cutaneous reactions is approximately 10% for uncomplicated rashes 2, but with mucosal involvement, the risk-benefit ratio does not favor rechallenge with any fluoroquinolone 2, 3.

Select an alternative antibiotic based on the original indication:

• For respiratory infections: Consider beta-lactams, macrolides, or doxycycline depending on pathogen and local resistance patterns
• The patient should be counseled that all fluoroquinolones are contraindicated going forward

Follow-Up

• Monitor for 24-48 hours after discontinuation to ensure no progression
• Symptoms should begin improving within 2-3 days of stopping the drug
• If worsening occurs (increased mucosal involvement, fever, skin detachment), urgent dermatology or allergy consultation is required
• Complete resolution typically occurs within 1-2 weeks 2

Future Considerations

This patient is permanently excluded from fluoroquinolone rechallenge or desensitization if mucosal involvement progresses or if features of SCARs develop 2. Even for non-severe reactions, the 2022 Drug Allergy Practice Parameter recommends avoiding the culprit agent, and cross-reactivity concerns make alternative fluoroquinolones risky 2.

Document this allergy prominently in the medical record to prevent future inadvertent exposure, as moxifloxacin-induced reactions can recur with greater severity upon re-exposure 4, 5.